To include your compound in the COVID-19 Resource Center, submit it here.

Repertoire bets on both sides of the TCR-antigen coin

Led by John Cox, Repertoire is mapping how TCRs, peptide-MHC complexes relate to each other, and to disease

Flagship’s Repertoire aims to identify which TCRs and antigens matter in disease and apply those insights to biomarkers and therapies, starting with a cytokine-loaded T cell candidate for cancer.

Repertoire Immune Medicines Inc. emerged in March via the merger of Flagship Pioneering’s immune mapping company Cogen Immune Medicine Inc. and its engineered cell therapy company Torque Therapeutics Inc. The predecessor companies had raised a combined $220 million in venture funds (see “Flagship’s Repertoire Combines

Read the full 749 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers